Emerging as a promising breakthrough in the fight against obesity, this medication is capturing considerable attention . It combines effects of two established GLP-1 binding agonists, liraglutide, with an new glucose-dependent peptide component. Preliminary patient data have indicated impressive fat decrease in people with obesity , possibly provid